INBP — Integrated Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $9.63m
- $6.17m
- $54.35m
- 99
- 98
- 30
- 90
Annual cashflow statement for Integrated Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 8.01 | 3.84 | -0.034 | 0.112 | 0.808 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -0.869 | 0.882 | 1.15 | 1.13 | 1.18 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.05 | 0.565 | -0.302 | -0.744 | -1.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | 3.05 | 4.09 | 1.23 | 0.943 | 2.06 |
| Capital Expenditures | -0.295 | -0.486 | -0.116 | -0.553 | -0.205 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.096 | 0.021 | 0.005 | 0 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | -0.199 | -0.465 | -0.111 | -0.553 | -0.205 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -3.04 | -3.5 | -0.136 | -0.029 | 0.078 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.192 | 0.121 | 0.985 | 0.361 | 1.94 |